Sweden
# |
Name |
Capital Expenditure |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD -487.87 M
|
Dec. 31, 2023 | USD 29.22 | -3.00% |
|
Sweden |
|
2 |
USD -19.65 M
|
Dec. 31, 2023 | USD 0.79 | -2.96% |
|
Sweden |
|
3 |
USD -16.45 M
|
Dec. 31, 2023 | USD 3.55 | -2.70% |
|
Sweden |
|
4 |
USD -12.25 M
|
Dec. 31, 2023 | USD 0.85 | -1.32% |
|
Sweden |
|
5 |
USD -5.35 M
|
Dec. 31, 2023 | USD 31.05 | 0.32% |
|
Sweden |
|
6 |
USD -2.26 M
|
Dec. 31, 2023 | USD 0.39 | -4.99% |
|
Sweden |
|
7 |
USD -1.93 M
|
Dec. 31, 2023 | USD 0.25 | -3.82% |
|
Sweden |
|
8 |
USD -1.31 M
|
Dec. 31, 2023 | USD 2.43 | -5.44% |
|
Sweden |
|
9 |
USD -1.26 M
|
Dec. 31, 2023 | USD 2.25 | -17.68% |
|
Sweden |
|
10 |
USD -777.62 K
|
Aug. 31, 2024 | USD 1.49 | -4.08% |
|
Sweden |
|
11 |
USD -734.62 K
|
Dec. 31, 2023 | USD 18.98 | -4.07% |
|
Sweden |
|
12 |
USD -207.96 K
|
Dec. 31, 2023 | USD 0.09 | 11.18% |
|
Sweden |
|
13 |
USD -179.93 K
|
Dec. 31, 2023 | USD 0.71 | 8.98% |
|
Sweden |
|
14 |
USD -84.88 K
|
Dec. 31, 2023 | NA | NA |
|
Sweden |
|
15 |
USD -72.05 K
|
Dec. 31, 2023 | USD 0.13 | 0.88% |
|
Sweden |
|
16 |
USD -28.92 K
|
Dec. 31, 2023 | USD 1.30 | -5.64% |
|
Sweden |
|
17 |
USD -18.56 K
|
Dec. 31, 2023 | USD 1.25 | -0.41% |
|
Sweden |
|
18 |
USD -8.04 K
|
Aug. 31, 2024 | USD 0.26 | 0.92% |
|
Sweden |
|
19 |
USD 0.00
|
Dec. 31, 2023 | USD 3.54 | -3.30% |
|
Sweden |
|
20 |
USD 0.00
|
Dec. 31, 2023 | USD 1.26 | -1.32% |
|
Sweden |
|
21 |
USD 0.00
|
Dec. 31, 2023 | USD 0.38 | -3.14% |
|
Sweden |
|
22 |
USD 0.00
|
Dec. 31, 2023 | USD 0.16 | -4.29% |
|
Sweden |
The Vaccines company in Sweden with the highest Capital Expenditure is Swedish Orphan Biovitrum AB (publ) (Stockholm Stock Exchange: SOBI.ST) at USD -487.87 M.
The Vaccines company in Sweden with the lowest Capital Expenditure is Cantargia AB (publ) (Stockholm Stock Exchange: CANTA.ST) at USD 0.00.
The top 10 Vaccines companies in Sweden by Capital Expenditure are Swedish Orphan Biovitrum AB (publ), Vicore Pharma Holding AB (publ), Vimian Group AB (publ), Moberg Pharma AB (publ), Probi AB (publ), Iconovo AB (publ), Alzinova AB (publ), BioInvent International AB (publ), Genovis AB (publ.) and Diamyd Medical AB (publ).
The bottom 10 Vaccines companies in Sweden by Capital Expenditure are Cantargia AB (publ), Pila Pharma AB (publ), SynAct Pharma AB, Infant Bacterial Therapeutics AB (publ), NextCell Pharma AB, Lipum AB (publ), IRLAB Therapeutics AB (publ), Enzymatica AB (publ), Bio-Works Technologies AB (publ) and Mendus AB (publ).